Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 47, Issue 12, 2006, Pages 2445-2446

  Yasui, Hiroshi ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CASPASE 3; CELECOXIB; CLADRIBINE; ETODOLAC; FLUDARABINE; FLUDARABINE PHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUSTAT; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P42; PROTEIN P44; PROTEIN P73; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; SDX 101; SULINDAC;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BCELL LEUKEMIA; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON POLYP; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; GASTROINTESTINAL TOXICITY; HUMAN; LONG TERM CARE; MULTIPLE MYELOMA; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ETODOLAC; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC;

EID: 33845597789     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601059779     Document Type: Note

References (8)

1. Ulrich, C and Bigler, J and Potter, J. (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics Nat Rev Cancer, 6, pp. 130-140.
2. Lu, D and Zhao, Y and Tawatao, R and Cottam, H and Sen, M and Leoni, L and (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia Proc Natl Acad Sci USA, 101, pp. 3118-3123.
3. Hedvat, M and Jain, A and Carson, D and Leoni, L and Huang, G and Holden, S and (2004) Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma Cancer Cell, 5, pp. 565-574.
4. Yasui, H and Hideshima, T and Hamasaki, M and Roccaro, A and Shiraishi, N and Kumar, S and (2005) SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma Blood, 106, pp. 706-712.
5. Robak, P and Linke, A and Cebula, B and Robak, T and Smolewski, P. (2006) Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells Leuk Lymphoma, 47, pp. 2625-2634.
6. Jenson, M and Engert, A and Goebeler, M and Weissinger, F and Wilhelm, M and Osterborg, A and (2003) A novel pro-apoptotic agent SDX-101 (R-etodolac) for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) Blood, 102, pp. 674A.
7. Grosch, S and Maier, T and Schiffmann, S and Geisslinger, G. (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors J Natl Cancer Inst, 98, pp. 736-747.
8. Boon, E and Keller, J and Wormhoudt, T and Giardiello, F and Offerhaus, G and van der Neut, R and (2004) Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines Br J Cancer, 90, pp. 224-229.